DCW DCW Q4 FY25 results (Jan–Mar 2025) and concall
DCW delivered a resilient performance in FY25, with revenue growing 7% and PAT doubling, largely driven by strong growth in its Specialty Chemicals segment and significant deleveraging. Despite facing headwinds in its Basic Chemicals segment due to global demand softness and import pressures, the company is executing strategic capacity expansions and operational improvements. Management remains optimistic about future growth, particularly from specialty chemicals and anticipated market normalization.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 489 | 474 | 538 |
| EBITDA | 35 | 57 | 56 |
| Net profit | -1 | 13 | 11 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
